Hepatic rather than cardiac steatosis relates to glucose intolerance in women with prior gestational diabetes

PLoS One. 2014 Mar 12;9(3):e91607. doi: 10.1371/journal.pone.0091607. eCollection 2014.

Abstract

Background: Increased myocardial lipid accumulation has been described in patients with pre- and overt type 2 diabetes and could underlie the development of left-ventricular dysfunction in metabolic diseases (diabetic cardiomyopathy). Since women with prior gestational diabetes (pGDM) display a generally young population at high risk of developing diabetes and associated cardiovascular complications, we aimed to assess whether myocardial lipid accumulation can be detected at early stages of glucose intolerance and relates to markers of hepatic steatosis (Fatty Liver Index), cardiac function, insulin sensitivity and secretion.

Methods: Myocardial lipid content (MYCL), left-ventricular function (1H-magnetic-resonance-spectroscopy and -imaging), insulin sensitivity/secretion (oral glucose tolerance test) and the fatty liver index (FLI) were assessed in 35 pGDM (45.6±7.0 years, 28.3±4.8 kg/m2) and 14 healthy control females (CON; 44.7±9.8 years, 26.1±2.5 kg/m2), matching for age and body-mass-index (each p>0.1).

Results: Of 35 pGDM, 9 displayed normal glucose tolerance (NGT), 6 impaired glucose regulation (IGR) and 20 had been already diagnosed with type 2 diabetes (T2DM). MYCL and cardiac function were comparable between pGDM and CON; in addition, no evidence of left-ventricular dysfunction was observed. MYCL was inversely correlated with the ejection fraction in T2DM (R = -0.45, p<0.05), while the FLI was tightly correlated with metabolic parameters (such as HbA1C, fasting plasma glucose and HDL-cholesterol) and rose along GT-groups.

Conclusions: There is no evidence of cardiac steatosis in middle-aged women with prior gestational diabetes, suggesting that cardiac complications might develop later in the time-course of diabetes and may be accelerated by the co-existence of further risk factors, whereas hepatic steatosis remains a valid biomarker for metabolic diseases even in this rather young female cohort.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Diabetes, Gestational*
  • Fatty Liver / complications*
  • Female
  • Glucose Intolerance / complications*
  • Glucose Intolerance / metabolism
  • Glucose Intolerance / physiopathology
  • Heart Diseases / complications*
  • Heart Function Tests
  • Humans
  • Insulin Resistance
  • Lipid Metabolism
  • Myocardium / metabolism
  • Pregnancy

Grants and funding

The study was supported by the “Jubiläumsfonds” of the Austrian National Bank (Grant Nr. 11198 to AKW, Grant Nr. 13249 and 15363 to M. Krssak.), the Austrian Heart Foundation and the Medical Scientific Fund of the Mayor of the City of Vienna (Grant 12023, both to M. Krebs). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.